Literature DB >> 16244542

Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Paul M Schneider1, Stephan E Baldus, Ralf Metzger, Martin Kocher, Rudolf Bongartz, Elfriede Bollschweiler, Hartmut Schaefer, Juergen Thiele, Hans P Dienes, Rolf P Mueller, Arnulf H Hoelscher.   

Abstract

OBJECTIVE: We sought to quantitatively and objectively evaluate histomorphologic tumor regression and establish a relevant prognostic regression classification system for esophageal cancer patients receiving neoadjuvant radiochemotherapy. PATIENTS AND METHODS: Eighty-five consecutive patients with localized esophageal cancers (cT2-4, Nx, M0) received standardized neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil, 36 Gy). Seventy-four (87%) patients were resected by transthoracic en bloc esophagectomy and 2-field lymphadenectomy. The entire tumor beds of the resected specimens were evaluated histomorphologically, and regression was categorized into grades I to IV based on the percentage of vital residual tumor cells (VRTCs). A major response was achieved when specimens contained either less than 10% VRTCs (grade III) or a pathologic complete remission (grade IV).
RESULTS: Complete resections (R0) were performed in 66 of 74 (89%) patients with 3-year survival rates of 54% +/- 7.05% for R0-resected cases and 0% for patients with incomplete resections or tumor progression during neoadjuvant therapy (P < 0.01). Minor histopathologic response was present in 44 (59.5%) and major histopathologic response in 30 (40.5%) tumors. Significantly different 3-year survival rates (38.8% +/- 8.1% for minor versus 70.7 +/- 10.1% for major response) were observed. Univariate survival analysis identified histomorphologic tumor regression (P < 0.004) and lymph node category (P < 0.01) as significant prognostic factors. Pathologic T category (P < 0.08), histologic type (P = 0.15), or grading (P = 0.33) had no significant impact on survival. Cox regression analysis identified dichotomized regression grades (minor and major histomorphologic regression, P < 0.028) and lymph node status (ypN0 and ypN1, P < 0.036) as significant independent prognostic parameters. A 2-parameter regression classification system that includes histomorphologic regression (major versus minor) and nodal status (ypN0 versus ypN1) was established (P < 0.001).
CONCLUSIONS: Histomorphologic tumor regression and lymph node status (ypN) were significant prognostic parameters for patients with complete resections (R0) following neoadjuvant radiochemotherapy for esophageal cancer. A regression classification based on 2 parameters could lead to improved objective evaluation of the effectiveness of treatment protocols, accuracy of staging and restaging modalities, and molecular response prediction.

Entities:  

Mesh:

Year:  2005        PMID: 16244542      PMCID: PMC1409844          DOI: 10.1097/01.sla.0000186170.38348.7b

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  46 in total

1.  Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression.

Authors:  Y Kajiyama; K Hattori; N Tomita; T Amano; Y Iwanuma; K Narumi; H Udagawa; M Tsurumaru
Journal:  Dis Esophagus       Date:  2002       Impact factor: 3.429

2.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

3.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

4.  Analysis of reduced death and complication rates after esophageal resection.

Authors:  B P Whooley; S Law; S C Murthy; A Alexandrou; J Wong
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

5.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

6.  Pathological features of rectal cancer after preoperative radiochemotherapy.

Authors:  O Dworak; L Keilholz; A Hoffmann
Journal:  Int J Colorectal Dis       Date:  1997       Impact factor: 2.571

Review 7.  Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.

Authors:  Johannes Zacherl; Andreas Sendler; Hubert J Stein; Katja Ott; Marcus Feith; Raimund Jakesz; J Rüdiger Siewert; Ulrich Fink
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

8.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

9.  Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy.

Authors:  Leyo Ruo; Satish Tickoo; David S Klimstra; Bruce D Minsky; Leonard Saltz; Madhu Mazumdar; Philip B Paty; W Douglas Wong; Steven M Larson; Alfred M Cohen; Jose G Guillem
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

Review 10.  Locally advanced esophageal cancer.

Authors:  Carol A Sherman; Andrew T Turrisi; Michael B Wallace; Carolyn E Reed
Journal:  Curr Treat Options Oncol       Date:  2002-12
View more
  111 in total

1.  Health-related quality of life after Ivor Lewis esophagectomy.

Authors:  Christian A Gutschow; Arnulf H Hölscher; Jessica Leers; Hans Fuchs; Marc Bludau; Klaus L Prenzel; E Bollschweiler; Wolfgang Schröder
Journal:  Langenbecks Arch Surg       Date:  2012-06-04       Impact factor: 3.445

2.  Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.

Authors:  Ralf Metzger; Ute Warnecke-Eberz; Hakan Alakus; Fabian Kütting; Jan Brabender; Daniel Vallböhmer; Peter P Grimminger; Stefan P Mönig; Uta Drebber; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

Review 3.  [Squamous cell carcinoma of the esophagus].

Authors:  K Ott; L Sisic; M Büchler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

4.  [Preoperative evaluation of prognostic factors in esophageal squamous cell cancer].

Authors:  P M Schneider; D Vallböhmer; J Brabender; A H Hölscher
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

5.  Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy.

Authors:  Guillaume S Chevrollier; Danica N Giugliano; Francesco Palazzo; Scott W Keith; Ernest L Rosato; Nathaniel R Evans Iii; Adam C Berger
Journal:  J Gastrointest Surg       Date:  2019-02-26       Impact factor: 3.452

6.  Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management.

Authors:  Elif Hindié; Christophe Hennequin; Jean-luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

7.  ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer.

Authors:  Ute Warnecke-Eberz; Daniel Vallböhmer; Hakan Alakus; Fabian Kütting; Georg Lurje; Elfriede Bollschweiler; Anke Wienand-Dorweiler; Uta Drebber; Arnulf H Hölscher; Ralf Metzger
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

Review 8.  Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher; Matthias Schmidt; Ute Warnecke-Eberz
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

9.  Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.

Authors:  Yushi Fujiwara; Shigeru Lee; Satoru Kishida; Ryoya Hashiba; Ken Gyobu; Ryoko Naka; Masaki Nishiyama; Toshio Ihara; Masashi Takemura; Harushi Osugi
Journal:  Int J Clin Oncol       Date:  2018-05-11       Impact factor: 3.402

10.  Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.

Authors:  S Blank; A Stange; L Sisic; W Roth; L Grenacher; F Sterzing; M Burian; D Jäger; M Büchler; K Ott
Journal:  Langenbecks Arch Surg       Date:  2012-12-07       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.